Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Notable: CPAP vs High-Flow Nasal Cannula for Treating Sleep Apnea in Children Recruitment opened The Hospital for Sick ChildrenNot applicable NCT07600333
  2. Notable: Promoting Physical Activity Among Young · Autism Recruitment opened Northeastern UniversityNot applicable NCT07747129
  3. Notable: Juveena™ Hydrogel System Following Transcervical Gynecologic Procedures (TCGP) At High-Risk for Intrauterine Adhesions Results posted: Nov 19, 2026 Rejoni Inc.Phase 3 NCT05394662
  4. Notable: Follow-up Study of SAT-3247 · Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101 Start date pushed from Aug 20, 2025 to Sep 25, 2025 Satellos Bioscience, Inc.Phase 2 NCT06867107
  5. Notable: PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) Results posted: Nov 19, 2026 GenmabPhase 1/2 NCT05721222
  6. Notable: REGN5381 · Heart Failure With Reduced Ejection Fraction Results posted: Nov 19, 2026 Regeneron PharmaceuticalsPhase 2 NCT06237309
  7. Notable: Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells · Multiple Myeloma Undergoing Autologous Stem Cell Transplant Results posted: Nov 19, 2026 GPCR Therapeutics, Inc.Phase 2 NCT05561751
  8. Notable: Oral ZL-65 Tablets in Healthy and Obese · Cardiovascular Risk Eligibility criteria changed Chengdu Zenitar Biomedical Technology Co., LtdPhase 1 NCT07946783
  9. Notable: ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration Start date pushed from Jul 13, 2018 to Jan 30, 2019 Astellas Institute for Regenerative MedicinePhase 1 NCT03178149
  10. Notable: Performance of the Next-Generation SAFESYNC Transcatheter Heart Valve · Severe Aortic Stenosis Enrollment increased: 40 → 210 participants Braile Biomedica Ind. Com. e Repr. Ltda.Not applicable NCT07806409
  11. Notable: Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin Eligibility criteria changed National Institute on Aging (NIA)Phase 2 NCT07721467
  12. Notable: Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers Start date pushed from Nov 23, 2026 to Jan 19, 2027 National Cancer Institute (NCI)Phase 2 NCT07686367
  13. Notable: Baricitinib · Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis Eligibility criteria changed National Institute of Allergy and Infectious Diseases (NIAID)Phase 1 NCT07262983
  14. Notable: H1ssF-3928 mRNA-LNP in Healthy Adults Results posted: Nov 19, 2026 National Institute of Allergy and Infectious Diseases (NIAID)Phase 1 NCT05755620
  15. Notable: FESS With or Without Intranasal Desmopressin in Chronic Rhinosinusitis With Nasal Polyps Start date pushed from Oct 15, 2026 to Jan 15, 2027 Services Institute of Medical Sciences, PakistanNot applicable NCT07855315
  16. Notable: Type O Whole Blood and Assessment of Age During Prehospital Resuscitation Trial Results posted: Nov 19, 2026 Jason SperryPhase 3 NCT04684719
  17. Notable: EFFET - Study of Executive Functions Regarding the Usability and User Experience of Assistive Technologies Among the Elderly Start date pushed from Oct 1, 2026 to Jan 15, 2027 University Hospital, AngersNot applicable NCT07834775
  18. Notable: High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN) Primary completion date changed from estimate of Sep 30, 2021 to Jan 30, 2025 St. Anna KinderkrebsforschungPhase 3 NCT01704716
  19. Notable: Telephone Delivered Weight Loss, Nutrition, Exercise WeLNES Study Results posted: Nov 19, 2026 Fred Hutchinson Cancer CenterPhase 3 NCT04447313
  20. Notable: CEUS Evaluation of Hydrocephalus in Neonates and Infants Start date pushed from Nov 30, 2026 to Dec 30, 2026 Children's Hospital of PhiladelphiaPhase 2 NCT06693752
  21. Notable: PEP-CMV Vaccine Targeting CMV Antigen · Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma Eligibility criteria changed Nationwide Children's HospitalPhase 2 NCT05096481
  22. Notable: MRI Study of OnabotulinumtoxinA (OnabotA) Effect on Jaw Muscle Pain Start date pushed from Oct 2026 to Dec 1, 2026 Weill Medical College of Cornell UniversityPhase 2 NCT07878780
  23. Notable: Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile® Start date pushed from Oct 2026 to Dec 2026 University of California, IrvinePhase 2 NCT07821112
  24. Notable: Rectus Sheath Block for Analgesia After Gynecological Laparotomy Results posted: Nov 19, 2026 Duke UniversityPhase 4 NCT06575699
  25. Notable: Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas Enrollment increased: 39 → 84 participants NYU Langone HealthEarly Phase 1 NCT06829173